Semaglutide Mechanism of Action: GLP-1 Receptor Agonism

The short version

Semaglutide is a selective GLP-1 receptor agonist. It mimics the action of native GLP-1 at its receptor but resists rapid enzymatic degradation, persisting in circulation long enough for once-weekly dosing. On binding the GLP-1 receptor it triggers a cascade that lowers blood glucose and body weight through at least four complementary pathways: stimulating insulin release, suppressing glucagon, slowing gastric emptying, and reducing appetite centrally.

GLP-1 in one paragraph

Glucagon-like peptide-1 is a 30-residue hormone secreted by L-cells of the distal small intestine and colon within minutes of a meal. It acts on the GLP-1 receptor (GLP-1R), a class B G-protein coupled receptor expressed on pancreatic beta cells, alpha cells, the vagus nerve, the gastrointestinal tract, kidney, heart, and several brain regions. Native GLP-1 has a plasma half-life of only 1 to 2 minutes because the enzyme dipeptidyl peptidase-4 (DPP-4) cleaves the first two N-terminal amino acids almost immediately after secretion. This makes native GLP-1 entirely unsuitable as a drug without chemical modification.

How structural changes shift the pharmacology

Semaglutide achieves prolonged receptor activity through two modifications to the GLP-1 backbone:^[1]

1. Aib at position 8. Native GLP-1 has alanine at position 8, the primary cleavage site for DPP-4. Replacing alanine with alpha-aminoisobutyric acid (Aib) creates steric bulk that prevents DPP-4 from engaging the N-terminus. The intrinsic receptor affinity of semaglutide is preserved because the structural change is small and directed away from the receptor-binding face of the peptide.
2. C18 fatty diacid at Lys26. Covalent attachment of a C18 fatty diacid through a linker to lysine at position 26 enables reversible, non-covalent binding to serum albumin. Albumin-bound semaglutide is protected from renal filtration (albumin has a molecular weight of 67,000 daltons, far above the glomerular cutoff) and is slowly released back into the free pool. This extended residence time in plasma translates into the observed terminal half-life of approximately 165 hours.

Both modifications together shift a peptide hormone with a 2-minute half-life into a once-weekly drug candidate without substantially altering receptor selectivity.

GLP-1 receptor coupling and downstream signaling

The GLP-1 receptor couples primarily to the stimulatory G-protein (Gs). When semaglutide binds, Gs activation leads to:

• Cyclic AMP (cAMP) accumulation inside the beta cell, which activates protein kinase A and the cAMP-regulated guanine nucleotide exchange factor Epac2. These second messengers facilitate calcium influx and the fusion of insulin-containing secretory granules with the plasma membrane, releasing insulin in a glucose-concentration-dependent manner. When blood glucose is low, the signal is attenuated, which limits hypoglycemia risk.
• Glucagon suppression from alpha cells, reducing hepatic glucose output, particularly in the fasting state.
• Slowed gastric emptying, blunting the postprandial glucose peak.
• Central appetite suppression, mediated through GLP-1 receptors in the arcuate nucleus of the hypothalamus and in brainstem circuits including the nucleus tractus solitarius and area postrema. This reduces caloric intake and drives a substantial part of the weight loss seen in clinical trials.

From receptor to clinical outcome

The integrated effect of these pathways is well demonstrated by the SUSTAIN-1 trial, where semaglutide 1 mg once weekly reduced HbA1c by approximately 1.55 percentage points versus placebo in drug-naïve type 2 diabetes, alongside a mean body weight reduction of approximately 4.5 kg.^[2]In SUSTAIN-6, semaglutide at 0.5 and 1 mg also reduced major adverse cardiovascular events by 26 % versus placebo, an effect attributed partly to weight loss and lipid improvement and partly to direct effects on vascular inflammation and atherosclerotic plaque biology still under investigation.^[3]

The cardiovascular benefit extended to people without diabetes in the SELECT trial, suggesting that GLP-1R agonism has effects beyond glycemic control; the mechanistic pathways underlying cardiovascular risk reduction remain an active area of research.

Receptor selectivity

Unlike tirzepatide (which also activates the GIP receptor), semaglutide is selective for the GLP-1 receptor with no meaningful agonist activity at the GIP or glucagon receptors at therapeutic concentrations. This makes its mechanism pharmacologically cleaner to interpret but also means it does not engage the additional metabolic effects of GIP receptor agonism.

Open mechanistic questions

• What fraction of the cardiovascular benefit in SELECT is attributable to weight loss versus direct receptor effects on vascular tissue and inflammation?
• How does central GLP-1R signaling modulate food preference and hedonic eating, distinct from simple caloric suppression?
• Are there clinically meaningful differences in receptor engagement kinetics between subcutaneous once-weekly semaglutide and oral daily semaglutide at matched plasma exposures?
• Does the slower gastric emptying contribution diminish at higher dose levels or with prolonged treatment, and how does this interact with the central appetite signal?